Skip to main content
eScholarship
Open Access Publications from the University of California

Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity.

  • Author(s): Lake, Jordan E
  • McComsey, Grace A
  • Hulgan, Todd
  • Wanke, Christine A
  • Mangili, Alexandra
  • Walmsley, Sharon L
  • Currier, Judith S
  • et al.
Abstract

Human immunodeficiency virus-infected women with central adiposity switched to raltegravir-based antiretroviral therapy immediately or after 24 weeks. No statistically significant changes in computed tomography-quantified visceral adipose tissue (VAT) or subcutaneous fat were observed, although 48 weeks of raltegravir was associated with a 6.4% VAT decline. Raltegravir for 24 weeks was associated with improvements in lipids.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View